SignaGen Laboratories is a U.S.-based biotechnology company specializing in the development and production of high-quality gene delivery technologies. Since its establishment, SignaGen has evolved into a reliable manufacturer supplying research-grade reagents and viral vectors to academic, biotechnology, pharmaceutical, and government institutions worldwide.

All SignaGen products are developed and manufactured in the United States, and all viral vector production—AAV, adenovirus, and lentivirus—is performed exclusively in the U.S. Our facilities include over 33,000 square feet of R&D laboratories and more than 6,000 square feet of cleanrooms, enabling complete in-house control of development, manufacturing, and quality assurance.

SignaGen offers three major categories of DNA and siRNA transfection reagents designed for efficient, reproducible, and low-toxicity gene delivery for both in vitro and in vivo applications.

In viral gene delivery, SignaGen is known for three advanced platforms:

• Ad.MAX™ Adenovirus System – a robust, scalable platform for high-titer adenovirus production.
• ANPS™ (AAV Native Promoter Swap) Packaging System – a next-generation AAV platform delivering up to 10-fold higher yields across multiple serotypes.
• LentiMAX™ Lentivirus System – a reliable third-generation system for stable transduction and CRISPR delivery.

All catalog and custom vectors are produced exclusively in our U.S. cleanrooms to ensure consistency, traceability, and regulatory compliance.

SignaGen products have been cited in over 7,000 publications, reflecting our commitment to quality and scientific excellence.

SignaGen Laboratories—Your One-Stop Gene Delivery Solution Provider.